英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

civilized    音标拼音: [s'ɪvəl,ɑɪzd]
a. 文明的,有礼的

文明的,有礼的

civilized
adj 1: having a high state of culture and development both
social and technological; "terrorist acts that shocked
the civilized world" [synonym: {civilized}, {civilised}]
[ant: {noncivilised}, {noncivilized}]
2: marked by refinement in taste and manners; "cultivated
speech"; "cultured Bostonians"; "cultured tastes"; "a genteel
old lady"; "polite society" [synonym: {civilized}, {civilised},
{cultivated}, {cultured}, {genteel}, {polite}]

Civilize \Civ"i*lize\, v. t. [imp. & p. p. {Civilized}; p. pr. &
vb. n. {Civilizing}.] [Cf. F. civilizer, fr.L. civilis civil.
See {Civil}.]
1. To reclaim from a savage state; to instruct in the rules
and customs of civilization; to educate; to refine.
[1913 Webster]

Yet blest that fate which did his arms dispose
Her land to civilize, as to subdue. --Dryden
[1913 Webster]

2. To admit as suitable to a civilized state. [Obs. or R.]
"Civilizing adultery." --Milton.

Syn: To polish; refine; humanize.
[1913 Webster]


Civilized \Civ"i*lized\, a.
Reclaimed from savage life and manners; instructed in arts,
learning, and civil manners; refined; cultivated.
[1913 Webster]

Sale of conscience and duty in open market is not
reconcilable with the present state of civilized
society. --J. Quincy.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Civilized查看　Civilized　在百度字典中的解释百度英翻中〔查看〕
Civilized查看　Civilized　在Google字典中的解释Google英翻中〔查看〕
Civilized查看　Civilized　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Secukinumab versus adalimumab for treatment of active psoriatic . . .
    Added value of this study To our knowledge, EXCEED is the first fully blinded head-to-head trial to evaluate the efficacy and safety of secukinumab (an IL-17A inhibitor) versus adalimumab (an anti-TNF agent) as first-line biological monotherapy in patients with active psoriatic arthritis with a musculoskeletal primary endpoint of ACR20 at week 52
  • Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
    Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission and in lower
  • Checking your browser - reCAPTCHA - PubMed
    Checking your browser before accessing pubmed ncbi nlm nih gov
  • Efficacy of secukinumab and adalimumab in patients with psoriatic . . .
    EXCEED is the first double‐blind head‐to‐head study to evaluate the efficacy and safety of secukinumab vs adalimumab as a first‐line biological monotherapy in patients with active PsA who were naïve to bDMARDs for PsA and psoriasis, and who were intolerant or had an inadequate response to csDMARDs
  • EXCEED Study: Cosentyx Equals Humira in Psoriatic Arthritis
    Novartis has announced the results of the EXCEED trial that pitted its IL-17 inhibitor, Cosentyx (secukinumab - SEC) against Humira (adalimumab - ADA) in patients with active psoriatic arthritis The trial demonstrated that SEC was not non-inferior to ADA, but failed to meet its primary endpoint of superiority over ADA as far as drug efficacy
  • Study Details | NCT02745080 | Efficacy of Secukinumab Compared to . . .
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
  • Novartis Cosentyx® shows encouraging results versus Humira®* from first . . .
    EXCEED is the first double-blinded head-to-head clinical trial evaluating Cosentyx (secukinumab) 300 mg versus Humira ® * (adalimumab) 40 mg EXCEED is a 52-week, multi-center, randomized, double-blind, active control, Phase IIIb trial evaluating the efficacy of Cosentyx compared with Humira ® * in patients with active PsA who are naïve to
  • FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN . . .
    Background: Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis 1 Secukinumab (SEC), an IL-17A inhibitor, provided significantly greater PASI 75 100 responses in a head-to-head trial versus (vs ) etanercept, a TNF inhibitor, in patients (pts) with moderate-to-severe plaque psoriasis 2 The objective of
  • Secukinumab Persistence in Patients with Psoriatic Arthritis: An . . .
    In addition, the EXCEED randomized clinical trial comparing secukinumab to adalimumab also reported superior persistence with secukinumab (86% versus 76%) [35]
  • Comparison of Secukinumab versus Adalimumab Efficacy by Sex in . . .
    Background Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries 1 The EXCEED study (NCT02745080) evaluated efficacy and safety of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in biologic-naïve patients with PsA Here, we report the impact of sex on […]





中文字典-英文字典  2005-2009